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Donepezil hydrochloride (HCl), a reversible acetylcholinesterase inhibitor with a selective central action, is effective in ameliorating language and cognitive deficits in dementia of Alzheimer type. 1 Preliminary clinical experience in single-case studies and small numbers of patients suggests that donepezil HCl may also stabilize cognitive deficits associated with subcortical vascular dementia 2 and may improve language deficits in patients with poststroke aphasia. 3, 4 We studied donepezil HCl in chronic poststroke aphasia.
Methods. Subjects and study design. This was a 20-week open-label pilot study evaluating the effects of donepezil HCl in chronic poststroke aphasia. The patients were recruited from a language therapy center, where they received two weekly sessions of conventional speech-language therapy. All patients and their responsible family member signed an informed consent agreement. The study was approved by the ethical committees of the centers. The primary outcome measure was the mean score change from baseline to endpoints at weeks 4 and 16 on the Aphasia Quotient (AQ) of the Western Aphasia Battery (WAB), 5 which is a measure of global severity. Secondary outcome measures were selected tests of the Spanish version of the Psycholinguistic Assessment of Language Processing in Aphasia (PALPA), 6 which enables a more fine-grained analysis of language processing deficits. These measures included phonemic discrimination for minimal word and nonword pairs, auditory lexical decision, repetition of words, repetition of nonwords, memory for digits, oral word-picture match, naming by frequency and oral sentencepicture match. After baseline assessment the patients received donepezil HCl 5-mg once daily for 4 weeks, followed by 10 mg once daily for 12 weeks, and thereafter a 4-week washout period. Testing was then repeated at weeks 4, 16, and 20. Safety and tolerability were reviewed at each visit.
Statistical analysis. The effect of donepezil HCl on aphasia severity was analyzed using the Wilcoxon signed-rank test.
Results. Patients demographics and disease characteristics. Eleven right-handed patients (10 men and 1 woman) were enrolled and 10 completed the trial. Patients' ages ranged from 27 to 72 years, with a mean of 56 years. Mean duration of aphasia was 4.4 (Ϯ3.5) years and mean years of education was 11.6 (Ϯ4.9). According to the WAB diagnostic criteria, 5 four patients had Broca's aphasia, six patients had conduction aphasia, and one patient had Wernicke's aphasia. Ten patients had left-sided perisylvian lesions (nine infarctions, one hemorrhage) and the remaining patient had a right-sided perisylvian infarction.
Primary and secondary outcome measures. Donepezil HCl increased the AQ score from baseline to endpoints at weeks 4 and 16 in all patients (table). The patients had AQ score increases of 12% at week 4 and of 20% at week 16, but showed decreases from week 16 to week 20 (washout) (see table) . Donepezil HCl also increased PALPA scores in 6 of the 9 domains (phonemic discrimination of nonwords, repetition of words, repetition of nonwords, oral wordpicture match, naming by frequency and oral sentence-picture match) (see table) . A decrease in oral word-picture match test from week 16 to week 20 (washout) was found. There were no differences in performance on AQ-WAB and PALPA between 5-mg and 10-mg daily doses.
Safety results. Donepezil HCL was safe and well tolerated. Treatment-emergent adverse events were mild, resulting in high compliance; only two patients developed irritability and increased sexual drive on starting donepezil HCl 10-mg, which did not require discontinuation of the treatment.
Discussion. The results of our study suggest that donepezil HCl may have beneficial effects on chronic poststroke aphasia. While agents that augment dopaminergic activity (i.e., bromocriptine) improve language output abnormalities, most likely by activating the mesocortical dopaminergic circuitry, 7 our findings and Table Mean those from previous case studies 3, 4 suggest that donepezil HCl may be effective in different linguistic domains. In our small sample, donepezil HCl had a beneficial effect at 5-mg and 10-mg daily doses on global aphasia severity (AQ) and PALPA tests examining input and output phonology and lexical-semantic processing. Thus, donepezil HCl seems to enhance neural activity in both the left and right hemispheres networks, presumably facilitating brain plasticity through long-term potentiation. 4 The interpretation of our results are limited by several methodologic shortcomings, namely the open and uncontrolled design, the small number of patients, the practice effects, and the patients' great expectation of improvement with a new therapeutic agent. Therefore, we consider these findings as preliminary, and randomized, double-blind, placebo-controlled trials are needed to provide further evidence of the potential benefit of donepezil HCl to patients with chronic poststroke aphasia.
